Market Newsdesk

MCLEAN, Va., Sept. 29, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII), America’s largest military shipbuilder and the global leader in autonomous seapower, was awarded a contract by the U.S. Navy to build 10 ROMULUS unmanned surface vessels (USVs) for the Medium Unmanned Surface Vessel (MUSV) program. The award marks a major advancement in the U.S. Navy’s transition from experimentation to fleet-scale deployment of trusted, operational autonomy across the maritime domain.

“HII has made deliberate, early investments in the development of autonomous systems, advancing capabilities essential to the Navy’s hedge strategy,” said Chris Kastner, HII president and CEO. “We remain firmly committed to supporting the U.S. Navy’s vision and accelerating this critical capability from production to operational deployment.”

The U.S. Navy’s selection underscores HII’s shipbuilding expertise and leadership in proven autonomous unmanned surface and underwater maritime systems to deliver reliable production at the speed and scale required for emerging unmanned fleet production and operations.

Photos accompanying this release are available at: https://www.hii.com/news/hii-wins-us-navy-contract-for-10-romulus-usvs-accelerating-deployment-of-proven-autonomous-capability.

At the core of ROMULUS is HII’s Odyssey Autonomous Control Solutions (ACS), a combat-tested autonomy suite that enables trusted, coordinated operations across surface and undersea domains. HII has delivered more than 750 REMUS unmanned underwater vehicles (UUVs) to customers in more than 30 countries. Together, ROMULUS, REMUS and Odyssey ACS provide a scalable foundation for autonomous maritime operations supporting the U.S. Navy and allied fleets.

In 2025, HII committed to securing the partners, production capacity, supplier network and infrastructure needed to move quickly from design and development to construction of ROMULUS USVs. That investment reflected HII’s continued support of the U.S. Navy’s unmanned maritime priorities and advancing the unmanned surface program with mature technology and a production-ready approach. By beginning work in 2025, HII positioned the ROMULUS program for accelerated delivery, reduced production risk and to provide the U.S. Navy with a scalable path to fielding autonomous unmanned surface capabilities at the pace the nation demands.

“Unmanned vessels ultimately must be built, integrated, tested and sustained as part of a fleet,” said Andy Green, president of HII’s Mission Technologies division. “As the nation’s largest shipbuilder, HII understands that challenge from both sides. By pairing our advanced cutting-edge technologies with our shipbuilding expertise, and leveraging experienced regional partners and suppliers, we are creating a production ecosystem capable of delivering reliable autonomous platforms at the pace and scale the U.S. Navy requires.”

Odyssey ACS: The Autonomy Behind ROMULUS

A key differentiator of ROMULUS is HII’s Odyssey ACS, a modular, open-architecture autonomy suite developed from decades of experience designing, building, operating and sustaining unmanned maritime systems.

Odyssey is designed to deliver consistent, predictable autonomous behavior, a requirement for the U.S. Navy’s transition from experimentation to operational deployment. It provides decision-making architecture that enables unmanned systems to perceive their surroundings, navigate, manage onboard systems and payloads, coordinate with other manned and unmanned platforms, and execute complex missions with limited human intervention.

Odyssey’s modular, open-architecture lets the U.S. Navy and allied partners rapidly integrate emerging sensors, command-and-control (C2) technologies and AI algorithms, ensuring ROMULUS remains upgrade-ready for evolving threat environments.

HII, with its partners Applied Intuition, Greenroom Robotics and Rodi Marine, successfully completed the evaluation phase of the MUSV program. HII’s Odyssey ACS vessel capabilities were validated through a series of operationally representative test events, demonstrating performance, reliability and mission readiness. The U.S. Navy-monitored testing took place in the Gulf of America over a 13-day period and evaluated the system under demanding, real-world operating conditions.

The most rigorous event was a long-endurance mission simulation. HII’s autonomy system successfully completed the full 420-nautical-mile mission over 28 hours, meeting all established success criteria and demonstrating the endurance and autonomous performance required for sustained maritime operations.

Designed and Built by Shipbuilders for Scale

For ROMULUS, HII is combining that expertise with a distributed production model that leverages regional shipbuilders and manufacturing partners. This approach expands available production capacity, strengthens the U.S. maritime industrial base and enables vessels to be produced efficiently and repeatedly as U.S. Navy demand grows.

HII is working with Gulf Coast build partners including Breaux Brothers Enterprises, Halimar Shipyard and Bayou Metal Supply & Manufacturing in Louisiana to support ROMULUS production, and developed in partnership with Beier Integrated Systems and Incat Crowther.

HII also recently announced a new10,000-square-foot expansion to increase the capacity of HII’s existing 40,000-square-foot unmanned manufacturing production campus capacity to build, develop and integrate advanced unmanned and autonomous maritime systems for both the REMUS family of UUVs and ROMULUS USVs.

The model allows major components and assemblies to be produced efficiently before final vessel integration, increasing throughput and creating a repeatable production architecture that can scale across the ROMULUS USV family.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:
Greg McCarthy
(202) 264-7126
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8ad2654-8701-4404-beb0-d34b186ce8a4

Châtillon, France, September 29, 2026

DBV Technologies Announces Submission of Biologics License Ap
p
lication to U.S. FDA for the VIASKIN

^®

Peanut Patch in Children Aged 4-7 Years

• The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. 
• DBV has requested Priority Review of the BLA.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN® Peanut Patch in children with peanut allergy aged 4 through 7 years.

DBV has requested Priority Review of the BLA. The FDA previously granted Breakthrough Therapy Designation to the VIASKIN® Peanut Patch.

“The submission of our BLA brings VIASKIN® Peanut Patch, a non-invasive, practical treatment option, one step closer to being available for children ages 4 through 7 living with peanut allergy, and marks a significant milestone in DBV’s transformation into a commercial organization,”
said Daniel Tassé, Chief Executive Officer of DBV Technologies.
“This BLA reflects years of rigorous clinical development, meaningful contributions from the entire food allergy community, and ongoing collaboration with the FDA. We are grateful for the Agency’s constructive engagement over the last few months and look forward to working closely with them during the review process.”

The VIASKIN® Patch uses epicutaneous immunotherapy (EPIT), an innovative, non-oral, non-injection approach to food allergy treatment that delivers small amounts of an allergen protein through the skin. By using the immune properties of the skin, the VIASKIN® Peanut Patch is designed to progressively desensitize children to peanut allergy.

The BLA is supported by the positive results from the VITESSE Phase 3 clinical trial of the VIASKIN® Peanut Patch in 654 children ages 4 through 7 years with peanut allergy. VITESSE is the largest immunotherapy clinical trial to date for this population.

About the VITESSE Study

VITESSE (NCT05741476) is a global Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of the VIASKIN® Peanut patch (250 µg) in children ages 4-7 years with peanut allergy. The study enrolled 654 children randomized 2:1 to receive either VIASKIN® Peanut Patch or placebo. Conducted at 86 sites across the United States, Canada, United Kingdom, Europe, and Australia, VITESSE represents the largest immunotherapy clinical trial for this patient population. The primary endpoint is the difference between the percentage of treatment responders in the active versus placebo group after 12 months of treatment. Following the 12-month double-blind period, children were given the option to continue into an open-label extension where all participants receive VIASKIN® Peanut Patch for up to a total of three years on treatment.

About DBV Technologies

DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® Patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN® Peanut patch and EPIT, results of DBV’s clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans, timing and expectations with respect to priority review of the BLA for VIASKIN® Peanut Patch for children ages 4 through 7, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026, DBV Technologies’ Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 filed with the SEC on April 30, 2026 and July 16, 2026, respectively, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

VIASKIN is a registered trademark of DBV Technologies.

Investor Relations Contact

Virginie Boucinha
DBV Technologies
[email protected]

Media Contact

Brett Whelan
DBV Technologies
[email protected] 

Attachment

• PDF Version

GRAND RAPIDS, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the holding company of Independent Bank, a Michigan-based community bank, announced that it expects to issue its 2026 third quarter results on Tuesday, October 27, 2026, at approximately 8:00 am ET. The release will be available on the Internet at IndependentBank.com within the “News” section of the “Investor Relations” area of the Company’s website.

Brad Kessel, President and CEO, Gavin Mohr, CFO and Joel Rahn, EVP Commercial Banking will review the quarterly results in a conference call for investors and analysts beginning at 11:00 am ET on Tuesday, October 27, 2026.

To access via phone, participants will need to register using the following link where they will be provided a phone number and access code: https://register-conf.media-server.com/register/BI8251941b98524fec94bd98aeea90727e

In order to view the webcast and presentation slides, please go to https://edge.media-server.com/mmc/p/oko972r9 during the time of the call. A replay of the webcast will be available until October 27, 2027.

About Independent Bank Corporation

Independent Bank Corporation (NASDAQ: IBCP) is a Grand Rapids, Michigan-based bank holding company and the parent company of Independent Bank and, as of July 1, 2026, Highpoint Community Bank. Independent Bank Corporation has total assets of approximately $6.3 billion and operates from 66 locations across Michigan’s Lower Peninsula. Founded in 1864 as First National Bank of Ionia, Independent Bank provides a full range of financial services, including commercial banking, consumer banking, mortgage lending, and investment services. Independent Bank expects to complete the full system integration of Highpoint Community Bank’s operations on November 9, 2026. Until conversion, customers of Highpoint Community Bank should continue using their existing Highpoint Community Bank branches, checks, bank cards, online and mobile banking, and other banking services as usual.

For more information, please visit our website at: IndependentBank.com.

BIRMINGHAM, Ala., Sept. 29, 2026 (GLOBE NEWSWIRE) — ServisFirst Bancshares, Inc. (NYSE: SFBS) is scheduled to announce earnings and operating results for the quarter ended September 30, 2026 on October 19, 2026 at 4 p.m. ET. The news release will be available at www.servisfirstbancshares.com.

ServisFirst Bancshares, Inc. will host a live audio webcast to discuss earnings and results on Monday, October 19, 2026 beginning at 5:15 p.m. ET. The audio webcast can be accessed at www.servisfirstbancshares.com. A replay of the call will be available until October 31, 2026.

About
ServisFirst
Bancshares,
Inc.

ServisFirst Bancshares, Inc. is a bank holding company based in Birmingham, Alabama. Through its subsidiary ServisFirst Bank, ServisFirst Bancshares, Inc. provides business and personal financial services from locations in Alabama, Florida, Georgia, North and South Carolina, Tennessee, Texas, and Virginia. Through the bank, we originate commercial, consumer and other loans and accept deposits, provide electronic banking services, such as online and mobile banking, including remote deposit capture, deliver treasury and cash management services and provide correspondent banking services to other financial institutions.

ServisFirst Bancshares, Inc. files periodic reports with the U.S. Securities and Exchange Commission (SEC). Copies of its filings may be obtained through the SEC’s website at www.sec.gov or at www.servisfirstbancshares.com.

More information about ServisFirst Bancshares, Inc. may be obtained over the Internet at www.servisfirstbancshares.com or by calling (205) 949-0302.

Contact: ServisFirst Bank
Davis Mange (205) 949-3420
[email protected]

BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea.

Details of the poster and presentation are as follows:

Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 (Rexaceract) in People with Parkinson’s Disease

E-Poster Number: 753

Presentation Date: October 7, 2026

Presentation Time: 12:00-12:10pm KST

Location: Hall D, 3^rd Floor, E-Poster Station 12

The International Parkinson and Movement Disorder Society (MDS) gathers thousands of the field’s clinicians, researchers, trainees, and industry supporters with an interest in the current research and approaches for the diagnosis and treatment of movement disorders on an annual basis at its International Congress of Parkinson’s Disease and Movement Disorders^®.

About

Rexaceract


Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is a beta-glucocerebrosidase (GCase) positive allosteric modulator, antiparkinsonian, that restores the function of the lysosomal enzyme GCase which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors, by stabilizing and chaperoning it to the lysosomes and mitochondria. In preclinical models of PD, rexaceract restored GCase enzymatic function, reduced endoplasmic reticulum stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-PD and idiopathic PD, rexaceract was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as nesting. Washout experiments in both GBA1-PD and idiopathic PD models, in which behavioral and neurochemical rescue effects seen with rexaceract were maintained even once it had been removed, suggest that rexaceract may have the potential to slow or stop the progression of the disease.

Results from a Phase 1 study of rexaceract in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with an increase in GCase activity among those receiving rexaceract at clinically relevant doses.

Rexaceract is currently being evaluated in a Phase 1b clinical trial for the treatment of PD with or without a GBA1 mutation. The primary endpoint of the trial, which enrolled participants across seven sites in Australia, is to evaluate the safety and tolerability of rexaceract after three months of dosing in people with PD. The Phase 1b study extension allows participants to continue to be treated with rexaceract for up to a total of 12 months.

Gain’s lead program in PD has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, rexaceract is currently being evaluated for the treatment of PD with or without a GBA1 mutation in a Phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates; expectations regarding the timing of patient enrollment and the completion and timing of results from a Phase 1b clinical study for rexaceract, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; the timing of the commencement of the Phase 2 clinical study for rexaceract; the ability for the Company to enroll patients in its planned Phase 2 clinical study for rexaceract; the Company’s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; the Company’s business development activities, strategic collaborations, licensing opportunities and financing activities; the advancement, prioritization and timing of the Company’s pipeline programs, including GT-04686; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2025 and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.

Investors:

Gain Therapeutics, Inc. 
Apaar Jammu 
Director, Investor Relations and Public Relations
[email protected]

LifeSci Advisors LLC
Chuck Padala
Managing Director
[email protected]

Media:

Russo Partners LLC
Nic Johnson and Elio Ambrosio
[email protected]
[email protected]
(760) 846-9256

SAN FRANCISCO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Perpetuals.com Ltd (NASDAQ: PDC), the AI-powered financial services company that is leveling the playing field for traders, today announced that Chief Strategy Officer and Director Matthew Nicoletti will present live at the AI & Technology Virtual Investor Conference on October 1, 2026.

DATE: October 1, 2026
TIME: 9:30 a.m. ET

REGISTER HERE

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.
  
Recent Company Highlights

UpsideOnly, a risk-free paper trading platform launched in May 2026, has attracted more than 500,000 users across approximately 170 countries. UpsideOnly enables individuals to make predictions on financial markets using virtual capital. The user insights are analyzed by BayesShield AI. When those insights contribute to profitable trading activity, eligible users share the resulting profits.

In mid-September, Perpetuals.com filed its Annual Report on Form 20-F for fiscal year 2026. The company’s total assets reached $65.2 million as of April 30, 2026, up more than 50-fold from the prior year, reflecting its transformation to a fintech.

About Perpetuals.com Ltd

Perpetuals.com Ltd (Nasdaq: PDC) is a fintech company that pairs proprietary AI with regulated market infrastructure to open global markets to more participants, from financial platforms to individual users. By building on fully compliant infrastructure, Perpetuals keeps the interests of platforms and users aligned while making markets more transparent and accessible.

UpsideOnly, the company’s flagship consumer product, is the first risk-free trading and market prediction platform that uses a proprietary AI algorithm combined with crowd intelligence to ensure users never lose money. Perpetuals’s patent-pending BayesShield AI analyzes billions of data points to identify the strongest signals from top-performing traders. Intentionally designed so that its success is directly aligned with that of its users, UpsideOnly enables eligible users to share in trading profits without ever risking their own money.

Perpetuals’s technology is used by the EU-licensed Perpetual Markets Multilateral Trading Facility (MTF), PM MTF Ltd, which operates under full MiFID II, MiCA, DORA, and EMIR compliance. With this regulatory foundation, Perpetuals delivers white label trading services that let partners launch on fully licensed infrastructure, cutting the time and cost of building their own.

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

CONTACTS:

Perpetuals

Media Contact:
[email protected]

Investor Relations:
[email protected]

Virtual Investor Conferences

Greg Young

VP Corporate Services

OTC Markets Group

(212) 652-5958

[email protected]

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased the American Depositary Receipts (“ADR’s)” of Qfin Holdings, Inc. (“Qfin” or the “Company”) (NASDAQ:QFIN) between March 18, 2026 and August 25, 2026, inclusive (the “Class Period”).

Investors who purchased Qfin ADR’s during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for November 30, 2026.

PLEASE CLICK HERE TO SUBMIT CONTACT AND TRADE INFORMATION

The filed complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that:

• Defendants had overstated the resiliency and stability of Qfin’s business and financial results despite regulatory changes;
• Defendants likewise downplayed the true scope and severity of the negative impact that regulatory headwinds were likely to have, and were already having, on the Company’s business and financial results; and
• as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On August 25, 2026, after the market closed, Qfin released its second quarter of 2026 financial results. Among other items, the Company reported that total net revenue fell 31.6% year-over-year to Renminbi (“RMB”) 3.57 billion, significantly missing consensus estimates. Furthermore, net income plummeted 76.8% year-over-year, heavily impacted by an unexpected RMB 500 million tax expense. Management also issued disappointing forward guidance, projecting a 67% to 73% year-over-year drop in Q3 non-GAAP net income due to rising funding costs and systemic liquidity shocks in the Chinese consumer credit market.

On this news, Qfin’s ADR’s fell $2.18 per ADR, or 18.91%, to close at $9.35 per ADR on August 26, 2026.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website:
Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.